|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
FR2643817B1
(fr)
|
1989-03-06 |
1993-12-17 |
Transgene Sa |
Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
|
|
DE3642912A1
(de)
|
1986-12-16 |
1988-06-30 |
Leybold Ag |
Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
|
|
US6222020B1
(en)
|
1987-01-07 |
2001-04-24 |
Imperial Cancer Research Technology Limited |
Antigens derived from the core protein of the human mammary epithelial mucin
|
|
FR2632863B2
(fr)
|
1987-10-29 |
1990-08-31 |
Transgene Sa |
Virus du fowlpox recombinant et vaccins derives de ces virus
|
|
US5100587A
(en)
|
1989-11-13 |
1992-03-31 |
The United States Of America As Represented By The Department Of Energy |
Solid-state radioluminescent zeolite-containing composition and light sources
|
|
FR2668064B1
(fr)
|
1990-10-23 |
1994-12-16 |
Transgene Sa |
Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
|
|
US5756102A
(en)
|
1990-11-20 |
1998-05-26 |
Virogenetics Corporation |
Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
WO1992015672A1
(en)
|
1991-03-07 |
1992-09-17 |
Virogenetics Corporation |
Genetically engineered vaccine strain
|
|
US5179993A
(en)
|
1991-03-26 |
1993-01-19 |
Hughes Aircraft Company |
Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
|
|
US6013638A
(en)
|
1991-10-02 |
2000-01-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
US6133028A
(en)
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
|
US5698443A
(en)
|
1995-06-27 |
1997-12-16 |
Calydon, Inc. |
Tissue specific viral vectors
|
|
WO1996002555A1
(en)
|
1994-07-15 |
1996-02-01 |
The University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
|
US20030026782A1
(en)
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
|
US6045802A
(en)
*
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
|
US6638762B1
(en)
|
1994-11-28 |
2003-10-28 |
Genetic Therapy, Inc. |
Tissue-vectors specific replication and gene expression
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
FR2727689A1
(fr)
|
1994-12-01 |
1996-06-07 |
Transgene Sa |
Nouveau procede de preparation d'un vecteur viral
|
|
IL116816A
(en)
|
1995-01-20 |
2003-05-29 |
Rhone Poulenc Rorer Sa |
Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
|
|
DE19520606B4
(de)
|
1995-06-06 |
2004-04-08 |
Roche Diagnostics Gmbh |
Vorrichtung zur optischen Untersuchung von Oberflächen
|
|
KR100470180B1
(ko)
|
1995-06-15 |
2005-02-04 |
크루셀 홀란드 비.브이. |
유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
|
|
EP2112225A1
(en)
|
1996-07-25 |
2009-10-28 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Recombinant pox virus for immunization against tumor-associated antigens
|
|
FR2751879B1
(fr)
|
1996-07-30 |
1998-10-30 |
Transgene Sa |
Composition pharmaceutique contre les tumeurs et infections a papillomavirus
|
|
EP1012276A2
(en)
|
1997-02-24 |
2000-06-28 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against muc1 tumor-associated antigen
|
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
|
FR2773885B1
(fr)
|
1998-01-16 |
2000-03-03 |
Elf Antar France |
Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
|
|
JP3119228B2
(ja)
|
1998-01-20 |
2000-12-18 |
日本電気株式会社 |
液晶表示パネル及びその製造方法
|
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
|
US6900049B2
(en)
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
|
US20020037274A1
(en)
|
1998-10-26 |
2002-03-28 |
Angelica Williams |
Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
|
|
FR2787465A1
(fr)
|
1998-12-21 |
2000-06-23 |
Transgene Sa |
Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
|
|
CA2362367C
(en)
|
1999-02-04 |
2004-08-03 |
Geron Corporation |
Telomerase reverse transcriptase transcriptional regulatory sequences
|
|
WO2000050573A1
(fr)
|
1999-02-22 |
2000-08-31 |
Transgene S.A. |
Procede d'obtention d'une preparation virale purifiee
|
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
AU776061B2
(en)
|
1999-11-15 |
2004-08-26 |
Onyx Pharmaceuticals |
An oncolytic adenovirus
|
|
AUPQ520800A0
(en)
|
2000-01-21 |
2000-02-17 |
Alfred Hospital |
Prime-boost vaccination strategy
|
|
CN101676389A
(zh)
|
2000-11-23 |
2010-03-24 |
巴法里安诺迪克有限公司 |
改良安卡拉痘苗病毒变体
|
|
FI116851B
(fi)
*
|
2001-05-03 |
2006-03-15 |
Fit Biotech Oyj Plc |
Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
|
|
GB0118532D0
(en)
|
2001-07-30 |
2001-09-19 |
Isis Innovation |
Materials and methods relating to improved vaccination strategies
|
|
WO2004011082A1
(en)
|
2002-07-26 |
2004-02-05 |
Myomend, Inc. |
Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
|
|
CA2503693A1
(en)
|
2002-10-29 |
2004-05-13 |
Coley Pharmaceutical Group, Ltd. |
Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
|
|
FR2862648B1
(fr)
|
2003-11-21 |
2006-02-03 |
Biomerieux Sa |
Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
|
|
JP5364371B2
(ja)
*
|
2005-06-28 |
2013-12-11 |
オンコセリオン インコーポレイテッド |
ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
|
|
AU2007327807A1
(en)
*
|
2006-12-05 |
2008-06-12 |
Transgene S.A. |
Means and method for raising improved immune response
|
|
SG193832A1
(en)
*
|
2008-05-29 |
2013-10-30 |
Transgene Sa |
Biomarker for selecting patients and related methods
|